semaglutide court case update Novo Nordisk faces off in with South African weight-loss drug compounder ruling on tirzepatide court case

In a 4-year CV outcomes trial (Trial 7), 4,825 patients were randomized to semaglutide tablets for a median follow-up of 49.6 months and 4,825 patients were randomized to placebo for a median follow-up of 49.4 months [see Clinical Studies (14.4)]

Whilst observational studies suggest that regular oral coffee consumption may benefit liver health, coffee enemas carry significant risks including rectal perforation, electrolyte disturbances, and infection

Available at: Novo Nordisk

doi: 10.1159/000541881 177 DaiJLuYRocaHKellerJMZhangJMcCauleyLKet al

Many patients also ask about GLP-1 side effects in women since tolerance can vary based on health and biology